7-BROMOPYRROLO[1,2-A]QUINOXALIN-4(5H)-ONE, 95.0%, 250mg

5-(Naphthalen-1-yl)-1-phenyl-1H-pyrazole-3-carboxylic acid, 95.0%, 2g

7-METHOXY-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-INDAZOLE, 95.0%, 500mg

(S)-2-Acetamido-6-((tert-butoxycarbonyl)amino)hexanoic acid, 95.0%, 100g

4-(4-Bromopyrimidin-2-yl)morpholine, 95.0%, 5g

3-Bromo-5-tert-butylphenylboronic acid, 98%, 5g

(R)-6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-6-ol, 95+%, 1g

3,5-Dibromo-2-iodopyridine, 95+%, 100mg

1-(2-Pyridylazo)-2-naphthol, min. 98%, pa, ACS, 1 g, glass packaging

(3-Fluoropyridin-2-yl)methanamine dihydrochloride, 95.0%, 10g

1-(Tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 95.0%, 10g

p-Anisidine , >=98%, for synthesis, 1 kg, plastic packaging.

(2,4-Dioxo-3,4-dihydro-2 H -pyrimidin-1-yl)-acetic acid, 95.0%, 5g